The findings highlight the importance of rheumatology, cardiology, and primary care working together to intervene early.

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.